

SWIXX AND BIOPAS EXPAND PORTFOLIO IN LATIN AMERICA, SECURING 9 NEW PARTNERSHIP CONTRACTS IN ONE YEAR

Baar, Switzerland, April 28th, 2025 – Swixx BioPharma AG of Baar, Switzerland, announced today an overview of new partnerships concluded by Biopas, a Swixx BioPharma company, for the period from January 2024 to January 2025. These agreements further strengthen the presence of Swixx Group in Latin America, reinforcing our position as a key player in the region.

Completed partnership agreements include:

1. In February 2024, Biopas entered a new partnership with **ASTRAZENECA**, S.A. DE C.V., that appointed Biopas to promote, sell and distribute **Arimidex[®]**, **Casodex[®]** and **Nolvadex[®]** in Mexico in the private channel.
2. Effective April 30th, 2024, Biopas expanded its current partnership with **UCB PHARMA**, SA and/or UCB Pharma GmbH, to include **Bimzelx[®]** in the territory of Colombia.
3. Effective as of July 2024, Biopas entered into a Distribution Agreement with **MEDICE Arzneimittel Pütter GmbH & Co. KG**, for **Medikinet[®]** (methylphenidate), indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 years and older, as well as in adults. The Agreement includes the territories of Argentina, Brazil, Ecuador, Colombia and Peru.
4. In August 2024, Biopas partnered with **BIAL - PORTELA & CA, S.A.** for **Ongentys[®]** (opicapone), indicated as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease who are experiencing "off" episodes. According to the Distribution Agreement, Biopas is appointed as an exclusive distributor to commercialize Ongentys in the territory of Argentina, Brazil, Colombia and Mexico. In January 2025, Biopas expanded its partnership with BIAL to include **Sedoxil[®]** (mexazolam) in the territories of Argentina, Brazil and Colombia. Additionally, in March 2025, an agreement was signed for the distribution of the antiepileptic **Zebinix[®]** (eslicarbazepine acetate) in Mexico and Brazil.
5. In September 2024, Biopas expanded the scope of the partnership with **JAZZ's GW PHARMA LTD**, with the Amendment of the Exclusive Distribution Agreement, to include **Epidyolex[®]** in the territory of Brazil (for the Parana State tender market).
6. Effective as of October 31st, 2024, Biopas entered a new partnership with **LABORATOIRES JUVISE PHARMACEUTICALS S.A.S**, expanding its gastroenterology portfolio with **Pylera[®]**, indicated, in combination with omeprazole, for the eradication of *H. pylori* and prevention of relapse of peptic ulcers in patients with active or a history of *H. pylori* associated ulcers. Under the License and Distribution Agreement, Biopas is appointed to import, distribute, sell, market and promote Pylera[®] in Brazil, Chile, Colombia, Ecuador, Mexico and Peru.
7. In December 2024, Biopas and **UCB** expanded their partnership with addition of new rare disease products, as announced earlier here: [News | Swixx BioPharma | Modern Medicines for All](#).
8. In addition, in December 2024, Biopas expanded its partnership scope with **Merz Therapeutics GmbH**, to include **Fampyra[®]** for the territory of Argentina, Colombia, Mexico and potentially Chile. Fampyra (fampridine) is indicated for improving walking in adults with multiple sclerosis who experience walking disabilities.



Jean-Michel Lespinasse, CEO of Swixx BioPharma, stated that “the acquisition of Biopas has been a key step in expanding Swixx’s footprint in Latin America, and it’s great to see such strong portfolio growth in the region. Securing nine new partnerships in one year not only strengthens our presence with Biopas, a Swixx BioPharma company, but also shows how our global network is creating new opportunities. This momentum confirms that Swixx is on the right path to becoming the go-to partner for multinational biopharma—offering a smart, flexible alternative to direct presence outside of top 20 global markets, while delivering localized solutions that match their in-house capabilities.”

Pascal Forget, Regional General Manager Latam and Board Observer of Swixx, commented that “these new partnerships are a major step forward in expanding access to innovative treatments for patients across Latin America. At Biopas, we are pleased to see some of our existing partnerships growing in the region, demonstrating the value and success that we bring to all our stakeholders. At the same time, it’s an honor to be chosen as a partner for new collaborations, and we’re excited to help bring these therapies to the people who need them most.”

About Swixx Group

Swixx operates 44 subsidiaries across Central and Eastern Europe, Greece, several CIS countries and the Middle East via Swixx BioPharma, via Biopas, a Swixx BioPharma company, in almost 20 countries in Latin America, and in Russia and Belarus via Swixx Healthcare. After the acquisition of Biopas, Swixx Group now has close to 1,700 employees and sales which exceeded 1.1 billion Euros in 2024. The company is one of the fastest-growing and largest independent commercialization platforms for biopharma globally. Swixx has gathered outstanding rare disease, oncology-hematology, specialty, vaccines and self-medication talent under one roof. For more information about Swixx, please visit: www.swixxbiopharma.com.



Swixx BioPharma investor and partner inquiries:

Jean-Michel Lespinasse, CEO

Stuart Swanson, Head of Corporate Development

bd.info@swixxbiopharma.com

Swixx BioPharma media inquiries:

Vedrana Sokac Brataljenovic, Public Affairs Director

vedrana.sokac@swixxbiopharma.com, Tel: +385 1 425 6086

Biopas inquiries:

Pascal Forget, Executive Regional General Manager Latam

bd@biopasgroup.com

